Thu, May 1, 9:25 PM (14 days ago)
**Indivior PLC (INDV) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** $266 million, down 6% YoY due to increased competition and lower pricing. - **Gross Margin:** 83%, down from 87% YoY due to manufacturing variances. - **Operating Income:** $66 million, down from $75 million YoY. - **Net Income:** $47 million, down from $61 million YoY. - **Earnings per Share (EPS):** $0.38, down from $0.45 YoY. **Cash Flow:** - **Operating Cash Flow:** $75 million, up from $(37) million YoY due to timing of government rebate invoices. - **Investing Cash Flow:** $(5) million, down from $25 million YoY due to lower maturities of investments. - **Financing Cash Flow:** $(17) million, down from $(56) million YoY due to lower share repurchases. **Key Trends & Uncertainties:** - **Product Performance:** SUBLOCADE revenue down 3% YoY, SUBOXONE Film revenue down 14% YoY. - **Litigation:** Ongoing opioid and dental litigation, with a $78 million provision for opioid litigation. - **Tariffs:** Uncertainty around potential U.S. tariffs on pharmaceutical products. - **Capital Expenditures:** $50-$70 million expected in 2025, primarily for Raleigh Manufacturing Facility. **Future Operations Impact:** - **Gross Margin:** Expected to remain in the low-to-mid 80% range. - **Research & Development:** Expected to continue below 2024 levels. - **Liquidity:** Company believes it has sufficient cash and cash equivalents to meet obligations. **Management Discussion:** - **Streamlining Actions:** Benefits from 2024 actions to narrow commercial focus and discontinue PERSERIS marketing. - **Label Update:** FDA approved label changes for SUBLOCADE, including rapid initiation protocol and alternative injection sites. - **Liquidity:** Company expects to sustain sales volume performance and maintain necessary liquidity.